Mirati Therapeutics, Inc.
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
Last updated:
Abstract:
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
9 Dec 2020
Issue date:
17 Aug 2021